People with lupus who were treated with hydroxychloroquine (HCQ), an anti-malarial drug, early after a diagnosis of lupus had less cumulative organ damage at three years after diagnosis than those who did not receive HCQ, according to a new analysis.
A study published in a recent issue of the journal Lupus reports that people with lupus had a 70 percent increased risk of developing shingles compared to participants without inflammatory disease.
A team of lupus researchers has identified a potential new biomarker that may be helpful in determining whether a person with lupus is at risk for developing organ damage.
A new study sheds light on the specific effects of drug treatments versus disease activity as risk factors for lymphoma, a type of cancer, among people with lupus.
The results of this study indicate that current use of steroids (20 mg/day or more) is perhaps the most significant risk factor for heart disease in individuals with lupus.
The researchers hoped to learn about the genetic contributions to lupus susceptibility and how this might relate to specific lupus-related phenotypes, such as the presence of specific autoantibodies.
The researchers hoped to learn about the relationship among hsCRP, lupus disease activity, and the risk of cardiovascular disease in individuals with lupus.
Metabolic syndrome is marked by increased risk of cardiovascular diseases, so its incidence among people with lupus can indicate risk of cardiovascular disease in lupus patients.